Biotech watchers lamenting a fall-off in public listings for biotech companies will take some heart from Acelyrin’s upsized initial public offering, which ended up at the
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg
Swiss pharma Roche has today officially launched a new institute that will focus on the use of human model systems – in vitro replicas of human tissues and organs – for dr
Akili Interactive has revealed the findings of a trial of its digital therapeutic (DTx) for attention-deficit hyperactivity disorder (ADHD) in adults, suggesting it may be
Eli Lilly has reported the results of its much-anticipated phase 3 trial of amyloid-targeting Alzheimer’s disease therapy donanemab, saying that almost half the patients t